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ABSTRACT 
 
Aims: To identify isosteres and bioisosteres suitable for substitution on the molecular scaffold of 
meclofenamic acid and tolfenamic acid. The compounds will be studied to determine drug-likeness 
and other properties. 
Study Design: Isosteres and bioisosteres were selected and emplaced on the scaffold of 
meclofenamic acid and tolfenamic acid to ascertain drug-likeness outcome. Drug candidates were 
selected based on favorable drug-likeness.  
Place and Duration of Study: Chemistry Department, University of Nebraska at Omaha, Omaha 
Nebraska from March 2015 to May 2015.  
Methodology: Two non-steroidal anti-inflammatory drugs, meclofenamic acid and tolfenamic acid, 
are selected based on versatile isosteres and bioisosteres substitution. Placement of class I 
isosteres, class II isosteres, and nonclassical bioisosteres was accomplished using molecular 
modeling software. Physicochemical properties were determined and compared by numerical 
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analysis and by pattern recognition. This approach is evaluated for success in generating drug-like 
compounds. 
Results: Utilizing meclofenamic acid as parent compound, a total of 13 class I isosteres, five class 
II isosteres, and four non-classical bioisosteres were identified. For this group the Log P and polar 
surface area values ranged from 2.534 to 6.268 and 49.326 Angstroms
2
 to 101.372 Angstroms
2
, 
respectively. Utilizing tolfenamic acid as parent compound, a total of ten class I isosteres, five class 
II isosteres, and four non-classical bioisosteres were identified. For this group the range of Log P 
and polar surface area values were 1.904 to 5.408, and 37.299 Angstroms2 to 75.349 Angstroms2, 
respectively. Multiple regression analysis of properties produced equations useful for prediction of 
similar drugs for both groups. 
Conclusion: Variations of physicochemical properties by isosteres (class I and class II) and 
bioisosteres, successfully produced 22 of meclofenamic acid based drug designs and 19 of 
tolfenamic acid based drug designs. All compounds were evaluated for drug-likeness and 
similarities by cluster analysis. New drug designs are needed for COX-1 inhibition. 
 
 
Keywords: COX-1; NSAIDs; cyclooxygenase; meclofenamic acid; tolfenamic acid. 
 
ABBREVIATIONS 
 
Term: PSA, polar surface area; MW, molecular weight; nON, number of oxygen and nitrogen atoms; 
nOHNH, number of hydroxyl and amine groups; nrotB, number of rotatable bonds; natoms, number of 
atoms; NSAIDs, non-steroidal anti-inflammatory drugs. 
 
1. INTRODUCTION  
 
Drugs identified as non-steroidal anti-
inflammatory drugs (NSAIDs) are generally 
indicated for acute or chronic conditions in which 
inflammation and pain are present [1]. Conditions 
in which NSAIDs are indicated include the 
following [1]: metastatic bone pain, postoperative 
pain, pain due to tissue injury, fever, ileus, renal 
colic, headaches, and acute gout. In addition, 
aspirin is indicated for inhibiting platelet 
aggregation and is able to irreversibly inhibit 
COX-1 (isoenzyme cyclooxygenase-1). Two 
forms of cyclooxygenase enzyme exist and are 
referred to as COX-1 and COX-2, both being 
structurally distinct from each other [2]. The 
isoform COX-2 is induced within inflammatory 
cells, while COX-1 is known to be a constitutive 
component of normal cells [2].   
 
Salicylic acid, an NSAID synthesized in 1860, 
has been used as an antipyretic, antiseptic, and 
antirheumatic [3]. Later, aspirin was developed 
as a more satisfactory alternative and preceded 
other drugs of similar action (hence aspirin-like 
drugs) and were termed as non-steroidal anti-
inflammatory drugs [3]. The inhibition of 
cyclooxygenase accounts for both therapeutic 
effects and the side effects of cyclooxygenase 
inhibition [4]. The NSAID that selectively inhibits 
COX-2 will maximize anti-inflammatory activity 
with considerably less toxicity [4]. Undesired side 
effects, such as damaging of the gastric mucosa 
and kidneys, results from NSAID activity of 
inhibition of COX-1 [4]. 
 
Inflammation of tissue can originate from 
infectious and non-infectious mechanisms of 
irritation and chronic injury [5]. It is generally 
accepted that inflammation is a cancer risk, with 
various conditions of inflammation found to be a 
predisposition to cancer [5]. Aspirin, as well as 
other NSAIDs, have shown clear assurance as 
effective chemoprevention agents upon cancers 
of the stomach, colon, lung, and breast [5].  
Previous studies have shown that NSAIDs will 
stimulate apoptosis (programmed cell death) and 
inhibit angiogenesis (formation of new blood 
vessels), both processes suppressing tumor 
growth and malignant transformation [6]. In 
particular, the selective inhibition of COX-2 
shows promise as anticancer agents [6]. Daily 
administration of aspirin reduces the risk for 
colon cancer by 63%, for breast cancer by 39%, 
for lung cancer by 36%, for esophageal cancer 
by 73%, and for prostate cancer by 39% [7].   
 
Studies have shown that long-term use of 
NSAIDs can reduce the risk of cancer of the 
breast, prostate, lung, skin, and colon [8,9,10, 
11,12]. The routine intake of aspirin and other 
NSAIDs have been shown to reduce the risk of 
pancreatic cancer and other digestive cancers 
[13,14,15]. Studies have indicated that NSAID 
use among males confers what is measured as 
modest protection for lung cancer [16]. Whereas, 
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regular aspirin consumption could reduce risk of 
lung cancer among Asian women [17]. 
 
The design of new COX-1 inhibitors would 
enhance the prevention and clinical treatment of 
various inflammatory associated sickness, 
including cancers. This study demonstrates the 
efficacy of modifying substituents of COX-1 
inhibitors meclofenamic acid and tolfenamic acid 
so that favorable drug-likeness properties 
remain. Both meclofenamic acid and tolfenamic 
acid are referred to as fenamic acid derivatives 
or fenamates. A systematic process that includes 
isosteric and nonclassical bioisosteric 
substitution is presented here, that demonstrates 
the effectiveness of this approach for the design 
of novel COX-1 inhibitors. 
 
2. MATERIALS AND METHODS  
 
2.1 Determination of Physicochemical 
Properties and Molecular Modeling  
 
Construction of all compound structures for 
determination of molecular properties and 
visualization (2-Dimensional)  was accomplished 
by utilizing the advanced molecular modeling 
software developed by ACD/Chem Sketch 
modeling version 10.00 (Advanced Chemistry 
Development, 110 Yonge Street, Toronto 
Ontario, M5C 1T4 Canada). Some 
physicochemical properties were determined by 
ACD/Chem Sketch (molecular weight) and 
primarily by Molinspiration (Molinspiration 
Chemiformatics, Nova ulica 61, SK-900 26 
Slovensky Grob, Slovak Republic). Various 
properties such as polar surface area, violations 
of Rule of 5, molecular volume, number of 
oxygen, nitrogen, amines (-NHn) and hydroxyls    
(-OH), were determined using Molinspiration 
Properties Calculations module (Molinspiration 
Cheminformatics, Nova ulica 61, SK-900 26 
Slovensky Grob, Slovak Republic). Potential 
biological activity of all compounds was 
determined by Molinspiration drug-likeness and 
bioactivity scoring, also by Molinspiration 
Cheminformatics (Molinspiration Chemin-
formatics, Nova ulica 61, SK-900 26 Slovensky 
Grob, Slovak. Republic). 
 
2.2 Analysis of Physicochemical 
Properties for Pattern Identification 
 
For identification of complex and hidden 
underlying associations or patterns within the 
multivariate numerical data matrix of the 
physicochemical properties, then various pattern 
recognition techniques were implemented. This 
included an approach applying hierarchical 
cluster analysis, which was accomplished by 
KyPlot version 2.0 Beta 15 (copyright Koichi 
Yoshioka 1997-2001). Other pattern recognition 
elucidation by K-means nonhierarchical cluster 
analysis were performed by PAST version 1.80 
(copyright Oyvind Hammer, D.A.T. Harper 1999-
2008). 
 
2.3 Numerical Analysis of Physico-
chemical Properties 
 
Descriptive statistical analysis, Pearson r, and 
coefficient of determination for all numerical data 
where indicated was performed by Windows 7 
Microsoft Office Professional Plus 2013 EXCEL 
(EXCEL 2013). Screening for numerical outliers 
was done by Grubb’s Test (extreme studentized 
deviate) by GraphPad Software (2236 Avenida 
de la Playa, La Jolla, CA 92037 USA). Multiple 
regression analysis was performed by GraphPad 
InStat version 3.0 for Windows 95 (HJ Motulsky, 
GraphPad InStat 3.0 GraphPad Software, Inc., 
San Diego California USA, www.graphpad.com). 
Analysis by ANOVA with F and P values was 
accomplished by PAST version 1.80 (copyright 
Oyvind Hammer, D.A.T. Harper 1999-2008). 
 
3. RESULTS AND DISCUSSION 
 
At variable rates, all NSAIDs will inhibit COX-1 
and COX-2 [18]. Generally, the mechanisms by 
which inhibition takes place falls into three 
categories [18]: Category 1: rapid competitive 
reversible binding of COX-1 and COX-2; 
Category 2: rapid but lower affinity reversible 
binding followed by time-dependent, slowly 
reversible, but higher affinity binding of COX-1 
and COX-2; Category 3: rapid reversible binding 
followed by covalent modification of COX-1 and 
COX-2. Exceptions to this include nimesulide 
(weak competitive inhibitor of COX-1, potent 
time-dependent inhibitor of COX-2) and 
celecoxib (slow competitive binding but 
irreversible binding at high concentrations) [18]. 
Therefore, generally COX inhibition is 
competitively reversible except for aspirin which 
incurs irreversible inhibition [19].   
 
Groups of atoms that are isosteric groups are 
isoelectronic in their outermost electron shell 
[20]. The isosteres are classified by the number 
of electrons in the outer shell (valence) and 
include the following classes [20,21]:  
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Class I: -CH3, -NH2, -SH, -OH, and halogens (-Cl, 
-I, -Br, -F).  
Class II: Oxygen atom, sulfur atom, Se, Te, -NH-, 
-CH2-. 
 
The application of isosteric replacement of atoms 
or groups from a drug molecule is broadly 
applied in the design of drugs, particularly in the 
design of antimetabolites (drugs altering 
mechanisms of metabolic processes) [20,21]. A 
large number of drugs have been discovered 
utilizing isosteres and bioisosteres replacement 
[21].   
 
The use of nonclassical isosteres or bioisosteres 
is essentially the “classical” approach to 
modification of structure [20]. Bioisosteres are 
entities that do not have the same number of 
atoms or identical electron structure to 
substituents they are meant to replace [20]. 
However, bioisosteres have chemical similarities 
that produce highly similar biological activities.  
Bioisosteres have been highly successful as a 
lead modification useful for reducing toxicity, 
altering activity of a lead compound, and 
alteration of the metabolism of the lead 
compound [20,21]. Examples of nonclassical 
bioisosteres include the following [21]: 
 
Nonclassical bioisosteres:  
 
-S(=O)2OH,  
-P(=O)(OH)NH2,  
-C(=O)NHCN,  
-P(=O)(OH)OCH2CH3 
 
These groups of atoms produce a favorable 
outcome when covalently bonded to the 
molecular scaffolding of meclofenamic acid and 
tolfenamic acid.   
 
3.1 Meclofenamic Acid Isosteres and 
Bioisosteres 
 
Meclofenamic acid is a NSAID having antipyretic 
and antigranulation activity, which is 
administered clinically for treatment of joint and 
muscular pain, arthritis, and menstrual pain [22].  
Studies have shown meclofenamic acid to be a 
potential antineoplastic agent for both androgen-
dependent and androgen-independent prostate 
cancer, following demonstration of its highly 
cytotoxic action against neoplastic prostate cells 
[23]. 
 
The parent structure of the NSAID meclofenamic 
acid is presented in Fig. 1, showing the two 
aromatic rings connected by a secondary amine 
(-NH-) with a carboxyl group (-COOH), two 
chlorine atoms, and one methyl group (-CH3).  It 
is the two chlorine atoms and one methyl group 
that are amenable to class I isosteres 
replacement.   
 
Systematic replacement of the original two 
chlorine atoms and methyl group by class I 
isosteres produces the derivatives of 
meclofenamic acid shown in Fig. 1.  Note that the 
two aromatic rings, carboxyl group (-COOH), and 
the connecting secondary amine group remains.  
The immediate consequence in physicochemical 
properties such as Log P, polar surface area 
(measured in Angstroms2 or A2), number of 
atoms (natoms), molecular weight, number of 
oxygen/nitrogen/amine/hydroxyl moieties, and 
molecular volume are calculated with 
presentation in Table 1.   
 
Property variations induced by class I isosteres 
replacement occurs for all 13 derivatives for all 
properties, save for number of atoms and 
number of rotatable bonds. Although there 
appears a broad range of Log P variation (from 
3.244 to 6.268) and polar surface area (from 
49.326 A2 to 101.372 A2), in fact, by the Grubb’s 
test there are no outliers (alpha = 0.05) [24] 
within these two parameters even with 
meclofenamic acid inclusive (Log P = 5.633, 
PSA= 49.326 A
2
).   
 
Derivatives 1, 4, 5, 8, and 10 now show zero 
violations of the Rule of 5 [25], as opposed to 
meclofenamic acid showing one violation, along 
with derivatives 2, 3, 6, 7, 9, 11, 12, and 13. The 
Rule of 5 rule states that, in general, an orally 
active drug has no more than one violation of the 
following criteria [25]: 
 
 No more than 5 hydrogen bond donors      
(-NHn and -OH) 
 Not more than 10 hydrogen bond 
acceptors (all nitrogen or oxygen atoms) 
 A molecular weight less than 500 Daltons 
 An octanol-water partition coefficient
]
 log P 
not greater than 5. 
 
Essentially, all thirteen class I isosteres of 
meclofenamic acid show favorable properties for 
oral administration.   
 
In the approach for class II isosteres replacement 
within meclofenamic acid, it is the connecting 
amine group (-NH-) that is replaced with –CH2-, 
Te, Se, -S-, or –O- (see Fig. 2). Note that the two 
aromatic rings, two chlorine atoms, carboxyl 
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group, and methyl group remain intact within the 
derivative structures, see Fig. 2.   
 
Variation of properties for class II isosteres is 
shown in Table 1, for comparison to the parent 
drug meclofenamic acid. In this case, by Grubb’s 
test, there are no outliers among Log P, 
molecular weight, volume, number of atoms, 
number of rotatable bonds, and polar surface 
area (meclofenamic acid included). These class 
II isosteres show one violation of Rule of 5, as 
does meclofenamic acid, preserving favorable 
oral activity.   
 
 
 
Fig. 1. Class I isosteres of meclofenamic acid   
 
 
 
Fig. 2. Class II isosteres of meclofenamic acid 
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An interesting comparison is found when 
nonclassical bioisosteres are applied for 
substituent replacement within meclofenamic 
acid. These are presented in Fig. 3. The resulting 
changes in physicochemical properties are 
revealed in Table 1. Notable, it is seen that 
compounds 19, 20, and 21 show zero violations 
of the Rule of 5, a distinguishable improvement 
compared to the parent compound meclofenamic 
acid. The use of non-classical bioisosteres 
improves oral activity of this NSAID, with 
compound 22 have one violation as does the 
parent compound.   
 
Likewise, there are no outliers among Log P, 
polar surface area, number of atoms, and 
molecular weight (including meclofenamic acid).  
This is of interest, because the nonclassical 
bioisosteres are of greater mass and volume 
than class I as well as class II isosteres.   
 
The molecular properties for meclofenamic acid 
isosteres and nonclassical bioisosteres is 
reported in Table 1. For the derivative 
compounds 1, 4, 5, 8, 10, 19, 20, and 21 there is 
actually improvement in drug-likeness (e.g. zero 
violations of Rule of 5), compared to the parent 
compound meclofenamic acid which has one 
violation of Rule of 5.  
 
3.1.1 Multiple regression for prediction and 
pattern recognition 
 
There are two general applications of multiple 
regression, that being 1) prediction, and 2) 
explanation [24]. The value of R
2
 (coefficient of 
determination) relates how well the model fits the 
data, explaining the relation of the independent 
variables (predictors) to the dependent variable 
(molecular weight in this study).  
 
The result of multiple regression analysis of 
properties of Table 1 (meclofenamic acid and 
derivatives) produces the following relationship 
that account for 62.47% of the variance in 
molecular weight (R2 = 0.6247). Where MW is 
molecular weight, natoms is number of atoms, 
nON is number of oxygen & nitrogen, nOHNH is 
number of hydroxyl & amines, nrotB is number of 
rotatable bonds, and volume is the molecular 
volume in Angstroms3.   
 
MW = 374.47 - 3.361 (PSA) - 59.244 (natoms) 
+ 64.031 (nON) + 2.701 (nOHNH) - 
31.614 (nrotB) +4.764 (volume) 
 
By assigning desired values for independent 
properties within the model, then it will be 
feasible to determine the expected molecular 
weight of the perspective drug compound. The 
result will be compounds analogous to the 
meclofenamic acid based group of COX-1 
inhibitors.  
 
The purpose of cluster analysis is to discover a 
system of organizing the compounds elucidated 
here into groups where members of each group 
share properties in common [24]. Hierarchical 
cluster analysis does not require preset 
knowledge of the number of groups. Two general 
methods of hierarchical clustering methods are: 
divisive and agglomerative [24]. The dendrogram 
presented in Fig. 4 is a vertical divisive outcome 
of Table 1 hierarchical cluster analysis, where 
meclofenamic acid (the parent compound) is 
represented as MA.   
 
The divisive approach begins by assuming a 
single group encompassing all members to be 
analyzed (group A, see Fig. 4) and further 
partitions that group into subgroups. This is 
followed by further partitioning of these 
subgroups further into subgroups and continues 
until each object forms its own subgroup.   
 
Conditions for this hierarchical cluster analysis is 
single linkage (i.e. the distance between two 
subgroups is the minimum distance between any 
two members of opposite groups) and Euclidean 
distance (the ordinary straight line distance 
between two points in Euclidean space) [24]. The 
initial group from which all members are divided 
begins at super node A (see Fig. 4). 
 
The length of the branch indicates the distance 
between the subgroups when they are joined.  
By the dendrogram of Fig. 4, the parent 
compound meclofenamic acid (MA) is most 
closely similar to compounds 9, 11, 12, 18, and 
7, in that corresponding order. The remaining 
compounds will likewise be clustered adjacent to 
compounds having greatest similarity based 
upon the physicochemical properties in Table 1.   
 
All compounds can then be associated to the 
other compounds is such a manner as to 
ascertain the highest level of similarity based on 
molecular properties that are important in 
elucidating drug-likeness. The node B then 
indicates a group of compounds of highest 
similarity, which includes: compounds 1, 5, 4, 8, 
and 10 (see Table 1). The length of the branch 
indicates the distance between the subgroups 
when they are joined.   
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Fig. 3. Nonclassical bioisosteres of meclofenamic acid  
 
 
 
Fig. 4. Hierarchical cluster analysis of meclofenamic acid based compounds utilizing single 
linkage cluster conditions Single linkage (the distance between two subgroups as the 
minimum distance between any two members of opposite groups) with Euclidean distance.  
The parent structure is meclofenamic acid designated as MA 
 
The applications of cluster analysis will suggest 
which compounds will have similarity in 
pharmacological activity, based on their 
physicochemical properties [20,21].  
 
3.2 Tolfenamic Acid Isosteres and 
Bioisosteres 
 
Tolfenamic acid is a fenamic acid derivative also 
referred to as fenamates. Previous studies have 
shown that tolfenamic acid is a successful 
anticancer agent that can significantly inhibit 
medulloblastoma, a common malignancy in 
children [26].   
 
The parent structure of this NSAID is presented 
in Fig. 5, showing the two aromatic rings 
connected by a secondary amine (-NH-) group, a 
carboxyl group (-COOH), one chlorine atom, and 
one methyl group (-CH3). It is the chlorine atom 
and methyl group that are amenable to class I 
isosteres replacement.   
 
Systematic replacement of the original chlorine 
atom and methyl group by class I isosteres 
produces the derivatives of tolfenamic acid 
shown in Fig. 5. Note that the two aromatic rings, 
carboxyl group (-COOH), and connecting 
secondary amine group remains. The immediate 
consequence in physicochemical properties such 
as Log P, polar surface area (measured in 
Angstroms2 or A2), number of atoms (natoms), 
molecular weight, number of oxygen/nitrogen/ 
amine/hydroxyl moieties, and molecular volume 
are calculated with presentation in Table 2.   
Cl
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Table 1. Meclofenamic acid isosteres and nonclassical bioisosteres 
 
Compound Log P Polar surface 
area (A
2
) 
Number 
of  atoms 
Molecular 
weight 
Number of 
oxygens & 
nitrogens 
Number of  
–OH and -NHn 
Violations 
of rule of 5 
Number of 
rotatable 
bonds 
Molecular  
volume (A
3
) 
1 4.605 49.326 19 263.243 3 2 0 3 221.279 
2 5.895 49.326 19 385.055 3 2 1 3 247.188 
3 5.491 49.326 19 479.055 3 2 1 3 259.397 
4 3.839 89.782 19 259.261 5 4 0 3 227.452 
5 4.736 49.326 19 291.397 3 2 0 3 246.738 
6 3.244 101.372 19 257.293 5 6 1 3 233.994 
7 5.174 49.326 19 255.317 3 2 1 3 244.539 
8 4.668 75.349 19 297.141 4 4 0 3 233.216 
9 5.414 49.326 19 314.193 3 2 1 3 239.588 
10 4.966 69.554 19 298.125 4 3 0 3 229.945 
11 5.863 49.326 19 316.571 3 2 1 3 235.463 
12 5.348 49.326 19 300.116 3 2 1 3 226.859 
13 6.268 49.326 19 408.022 3 2 1 3 245.918 
14 5.083 37.299 19 295.165 2 1 1 3 242.888 
15 5.035 37.299 19 408.738 2 1 1 3 257.464 
16 5.534 37.299 19 360.098 2 1 1 3 249.577 
17 5.089 37.299 19 313.205 2 1 1 3 244.215 
18 5.296 46.533 19 297.137 3 1 1 3 235.071 
19 2.534 66.397 20 332.208 4 2 0 3 250.936 
20 4.059 75.349 20 331.139 4 4 0 3 259.14 
21 4.507 64.917 21 320.179 4 2 0 3 259.732 
22 5.008 58.56 22 360.177 4 2 1 5 290.199 
Meclofenamic 
acid 
5.633 49.326 19 296.153 3 2 1 3 238.488 
A
2
 = Angstroms
2
, A
3
 = Angstroms
3
;  
The following compounds have violations of Log P (not less than Log P = 5): compounds 2, 3, 7, 9, 11, 12, 13, 14, 15, 16, 17, 18, 22, and meclofenamic acid.   
The following compounds have violations of the number of –OH and –NHn (not less than 5 total): compound 6 
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Table 2. Tolfenamic acid isosteres and nonclassical bioisosteres 
 
Compound Log P Polar surface 
area (A
2
) 
Number of 
Atoms 
Molecular 
weight 
Number of 
oxygens & 
nitrogens 
Number 
of –OH & -NH 
Violations of 
rule of 5 
Number of 
rotatable 
bonds 
Molecular 
volume 
(A
3
) 
1 4.489 49.326 18 245.253 3 2 0 3 216.348 
2 5.134 49.326 18 306.159 3 2 1 3 229.302 
3 5.408 49.326 18 353.159 3 2 1 3 235.407 
4 4.314 69.554 18 243.262 4 3 0 3 219.435 
5 4.555 49.326 18 259.33 3 2 0 3 229.077 
6 3.808 75.349 18 242.278 4 4 0 3 222.705 
7 4.774 49.326 18 241.29 3 2 0 3 227.978 
8 4.038 75.349 18 262.696 4 4 0 3 219.68 
9 4.784 49.326 18 279.748 3 2 0 3 226.052 
10 4.336 69.554 18 263.68 4 3 0 3 216.409 
11 4.453 37.299 18 260.72 2 1 0 3 229.352 
12 4.405 37.299 18 374.293 2 1 0 3 243.928 
13 4.904 37.299 18 325.653 2 1 0 3 236.041 
14 4.459 37.299 18 278.76 2 1 0 3 230.679 
15 4.667 46.533 18 262.692 3 1 0 3 221.535 
16 1.904 66.397 19 297.763 4 2 0 3 237.401 
17 3.429 75.349 19 296.694 4 4 0 3 245.604 
18 3.877 64.917 20 285.734 4 2 0 3 246.197 
19 4.378 58.56 21 325.732 4 2 0 5 276.663 
Tolfenamic acid 5.003 49.326 18 261.708 3 2 1 3 224.953 
A2 = Angstroms2, A3 = Angstroms3 
The following compounds have violations of Log P (not less than Log P = 5): compounds 2, 3, and tolfenamic acid
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Fig. 5. Class I isosteres of tolfenamic acid 
 
Property variations induced by class I isosteres 
replacement occurs for all 10 derivatives for all 
properties, save for number of atoms and 
number of rotatable bonds. Although there 
appears a range of Log P variation (from 3.808 to 
5.408) and polar surface area (from 49.326 A
2
 to 
75.349 A2), in fact, by the Grubb’s test there are 
no outliers (alpha = 0.05) [24], within these two 
parameters even with tolfenamic acid inclusive 
(Log P = 5.003, PSA= 49.326 A
2
).   
 
Applying the Rule of 5 test to the ten isosteres of 
tolfenamic acid shows that only compound 2, 3, 
and tolfenamic acid have one violation. Hence, 
these class I isosteres show favorable properties 
for drug-likeness and oral administration. 
 
In the approach for class II isosteres replacement 
within tolfenamic acid, it is the connecting amine 
group (-NH-) that is replaced with –CH2-, Te, Se, 
-S-, or –O- (see Fig. 6). Note that the two 
aromatic rings, chlorine atom, carboxyl group, 
and methyl group remain intact within the 
derivative structures, see Fig. 6.   
 
Variation of properties for class II isosteres is 
shown in Table 2, for comparison to the parent 
drug tolfenamic acid. In this case, by the Grubb’s 
test, there are no outliers among Log P, 
molecular weight, number of atoms, number of 
rotatable bonds, and polar surface area 
(tolfenamic acid included). These class II 
isosteres show zero violations of Rule of 5, thus 
class II isosteres replacement preserves 
favorable drug-likeness and oral activity.   
 
An interesting comparison is found when 
nonclassical bioisosteres are applied for 
substituent replacement within tolfenamic acid.  
These are presented in Fig. 7. The resulting 
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changes in physicochemical properties is 
revealed in Table 2. Notably, it is seen that all 
four compounds 16, 17, 18, and 19 show zero 
violations of the Rule of 5, a distinguishable 
improvement compared to the parent compound 
tolfenamic acid which shows only one violation of 
Rule of 5. The use of non-classical bioisosteres 
improves oral activity of this NSAID.   
 
Likewise, there are no outliers among Log P, 
polar surface area, number of atoms, molecular 
volume, and molecular weight (including 
meclofenamic acid). This is of interest, because 
the nonclassical bioisosteres are of greater mass 
and volume than class I as well as class II 
isosteres.   
 
The overall drug-likeness and oral activity of 
tolfenamic acid isosteres & bioisosteres is 
retained, with all instances (save for 2 and 3 
which are equal to the parent compound 
tolfenamic acid) are actually improved in terms of 
drug-likeness (e.g. zero violations of Rule of 5). 
 
 
 
 
Fig. 6. Class II isosteres of tolfenamic acid 
 
 
 
Fig. 7. Nonclassical bioisosteres of tolfenamic acid 
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By the t-test the means of Log P values for class 
I isosteres for both meclofenamic acid and 
tolfenamic acid derivatives are equal (P=0.13).  
By the t-test and one-way ANOVA, the Log P for 
nonclassical bioisosteres of both groups have 
equal means (P=0.44). However, this is not true 
for the class II isosteres of both groups. The 
means for Log P values for class II isosteres of 
meclofenamic acid compounds 14 to 18 
compared to tolfenamic acid compounds 11 to 15 
is 5.207 (standard deviation of 0.21) and 4.578 
(standard deviation of 0.21), respectfully.  
Consequently, the substitution of class II 
isosteres (replaced with –CH2-, Te, Se, -S-, or –
O- groups) upon the tolfenamic acid structure 
having only one chlorine atom has substantial 
impact upon partition coefficient Log P.  
 
3.2.1 Multiple regression for prediction and 
pattern recognition 
 
The result of multiple regression analysis of 
properties of Table 2 produces the following 
relationship that account for 74.23% of the 
variance in molecular weight (R2 = 0.7423).  
Where MW is molecular weight, natoms is 
number of atoms, nON is number of oxygen & 
nitrogen, nOHNH is number of hydroxyl & 
amines, nrotB is number of rotatable bonds, and 
volume is molecular volume in Angstroms3:   
 
MW = 338.75 + 1.131(PSA) – 72.025 (natoms)   
+ 23.025 (nON) – 24.929 (nOHNH)            
- 17.483 (nrotB) + 5.344 (volume) 
 
By assigning desired values for independent 
properties within the model, then it will be 
feasible to determine the expected molecular 
weight of the perspective drug compound. The 
result will be compounds analogous to the 
tolfenamic acid based group of COX-1 inhibitors.  
 
The dendrogram presented in Fig. 8 is a vertical 
divisive outcome of Table 2 hierarchical cluster 
analysis, where tolfenamic acid (the parent 
compound) is represented as TA (see Fig. 8).  
Conditions for this hierarchical cluster analysis is 
single linkage (i.e. the distance between two 
subgroups is the minimum distance between any 
two members of opposite groups) and Euclidean 
distance (the ordinary straight line distance 
between two points in Euclidean space) [24].  
The initial group from which all members are 
divided begins at super node A (see Fig.8).  
 
The length of the branch indicates the distance 
between the subgroups when they are joined.  
By the dendrogram of Fig. 8, the parent 
compound tolfenamic acid (TA) is most closely 
similar to compounds 2 and 3, in that 
corresponding order.  The remaining compounds 
will likewise be clustered adjacent to compounds 
having greatest similarity based upon the 
physicochemical properties in Table 2.   
 
All compounds can then be associated to the 
other compounds is such a manner as to 
ascertain the highest level of similarity based on 
molecular properties that are important in 
elucidating drug-likeness. The node B then 
indicates a group of compounds of highest 
similarity, which includes: compounds 1, 5, 7, 9, 
15, 11, 14, 13, and 12 (see Table 2 for molecular 
properties). The length of the branch indicates 
the distance between the subgroups when they 
are joined. 
 
The applications of cluster analysis will suggest 
which compounds will have similarity in 
pharmacological activity, based on their 
physicochemical properties [20,21].  
 
3.3 Comparison of Meclofenamic and 
Tolfenamic Acid Isosteres/ Bioisos-
teres 
 
The replacement of substituents found on 
meclofenamic acid and tolfenamic acid results in 
significant changes of some properties from 
those of the parent compounds. However, the 
drug-likeness of the derivatives is generally 
improved (i.e. zero violations of the Rule of 5 or 
only one violation). The analysis of properties by 
cluster analysis is able to identify underlying 
relationships and divide the compounds into 
groups having the highest level of similarity. By 
this manner, the derivatives most similar to the 
parent compounds were identified.  
 
The average values for the pharmacological 
properties important for consideration of drug-
likeness are presented in Table 3.   
 
The overall comparison for all of meclofenamic 
acid and tolfenamic acid based COX-1 inhibitors, 
their molecular properties, are presented in   
Table 3. By one-way ANOVA analysis it is 
determined that the two group means are equal 
(P=0.99). In addition, the Kruskal-Wallis test 
indicates the two groups have equal medians 
(P=0.97). The two groups have extremely strong 
positive correlation (Pearson’s r = 0.9990).   
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The investigation and design of new COX-1 
inhibitors is feasible and needed. Previous 
studies have shown that COX-1 expression is 
up-regulated in cancer such as human breast 
cancer and human prostate cancer [27]. COX-1 
but not COX-2, is highly expressed in human 
epithelial ovarian cancers [27]. Up-regulation of 
COX-1 is found in squamous cell carcinoma and 
adenocarcinoma of the human cervix, suggesting 
that both COX-enzymes and/or their products 
may contribute to modulate the tumors genesis 
and the expression of factors responsible of the 
development of cervical cell neoplasia [27]. 
Clearly then, the investigation and design of 
novel COX-1 inhibitors is appropriate and 
imperative. This study affirms the efficacy of 
computer aided drug design in pursuit of COX-1 
inhibitors. The numerous compounds presented 
in this study are based upon proven approaches 
to drug modification and lead design. Computer 
aided drug design will continue to be a powerful 
tool in the efforts to explore new drug designs as 
remedies for inflammatory based disease. 
 
 
Fig. 8. Hierarchical cluster analysis of tolfenamic acid based compounds utilizing single 
linkage cluster conditions with Euclidean distance. The parent structure is tolfenamic acid 
designated as TA 
 
Table 3. Comparison of properties of isosteres and non-classical bioisosteres of meclofenamic 
and tolfenamic 
 
Property Average values for Average values for 
all meclofenamic acid all tolfenamic acid 
based cox-1 inhibitors based Cox-1 inhibitors 
Log P 5.0±1.0 4.0±1.0 
Polar surface area (A
2
) 59.099±17 54.802±13 
Number of atoms 19±1.0 18±1.0 
Molecular weight 323.43±55 283.33±38 
Number of –O and -N 3.0±1.0 3.0±1.0 
Number of –OH and –NHn 2.0±1.0 2.0±1.0 
Violations of Rule of 5 1.0±0.0 0±0.0 
Number of rotatable bonds 3.0±0.0 3.0±0.0 
Molecular volume (A
3
) 244.32±15 231.73±14 
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4. CONCLUSION 
 
Both meclofenamic acid and tolfenamic acid 
express anticancer activity. That action and other 
aspects prove both these compounds to be 
desirable lead drugs for new compound 
structures. All derivatives of both drugs retain 
favorable drug-likeness as measured by the Rule 
of 5 (i.e. zero violations or only one).   
Comparison of average values for molecular 
properties indicated that the two populations 
have equal means, equal medians, and have 
extremely strong positive correlation. Cluster 
analysis revealed which derivatives were of 
highest similarity to their parent compound.  
Multiple regression analysis of all 
physicochemical properties produced models 
describing 62.47% of variance in meclofenamic 
acid compounds (R
2
 = 0.6247) and 74.23% of 
variance in tolfenamic acid compounds (R2 = 
0.7423). The use of isosteres and nonclassical 
bioisosteres proved a successful approach for 
designing novel COX-1 inhibitors. Computer 
aided drug design is a powerful tool to explore 
new drug designs for treatment of inflammatory 
based disease. 
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